A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients with Moderate to Severe Atopic Dermatitis

Main Article Content

Andreas Wollenberg
Michael D Howell
Emma Guttman-Yassky
Jonathan I Silverberg
Claire Birrell
Christopher Kell
Koustubh Ranade
Michelle Dawson
Rene van der Merwe

Keywords

tralokinumab, atopic dermatitis, biologic therapy

Abstract

Abstract not available.

 

Disclosures: Study sponsored by LEO Pharma

 

Copyright 2018 SKIN